Synonym
Nifedipine, Adalat, Procardia, Bay-1040, Cordipin, Corinfar, Bay 1040, Bay1040
IUPAC/Chemical Name
dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
InChi Key
HYIMSNHJOBLJNT-UHFFFAOYSA-N
InChi Code
InChI=1S/C17H18N2O6/c1-9-13(16(20)24-3)15(14(10(2)18-9)17(21)25-4)11-7-5-6-8-12(11)19(22)23/h5-8,15,18H,1-4H3
SMILES Code
O=C(C1=C(C)NC(C)=C(C(OC)=O)C1C2=CC=CC=C2[N+]([O-])=O)OC
Appearance
Light yellow to yellow crystalline solid.
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
Nifedipine (BAY-a-1040) is a potent calcium channel blocker and drug of choice for cardiac insufficiencies.
In vitro activity:
This study investigated the effects of nifedipine on iron content and expression of TfR1, DMT1 and ferroportin1 (Fpn1) in WKPT-0293 Cl.2 cells of the S1 segment of the proximal tubule in rats, using a graphite furnace atomic absorption spectrophotometer and Western blot analysis, respectively. This study demonstrated for the first time that nifedipine significantly enhanced iron content as well as TfR1 and DMT1 expression and had no effect on Fpn1 levels in the cells.
Reference: Front Pharmacol. 2017 Feb 13;8:60. https://pubmed.ncbi.nlm.nih.gov/28243203/
In vivo activity:
After pre-treatment with nifedipine or vehicle, anesthetized rats received infusions or bolus injections of NPY. Infusion NPY (1 µg/kg/min) increased diuresis and natriuresis, and this was attenuated by intraperitoneal injection of nifedipine (3 µg/kg).
Reference: Molecules. 2021 Jul 24;26(15):4460. https://pubmed.ncbi.nlm.nih.gov/34361613/
|
Solvent |
mg/mL |
mM |
comments |
| Solubility |
| DMF |
30.0 |
86.62 |
|
| DMSO |
66.3 |
191.53 |
|
| DMSO:PBS (pH 7.2) (1:1) |
0.1 |
0.29 |
|
| Ethanol |
9.0 |
25.99 |
|
| Water |
1.0 |
2.89 |
|
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
346.33
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
1. Yu SS, Jiang LR, Ling Y, Qian ZM, Zhou YF, Li J, Ke Y. Nifedipine Increases Iron Content in WKPT-0293 Cl.2 Cells via Up-Regulating Iron Influx Proteins. Front Pharmacol. 2017 Feb 13;8:60. doi: 10.3389/fphar.2017.00060. PMID: 28243203; PMCID: PMC5303744.
2. Liu P, Gong J, Ding X, Jiang Y, Chen G, Li B, Weng Q, Chen Q. The L-type Ca(2+) Channel Blocker Nifedipine Inhibits Mycelial Growth, Sporulation, and Virulence of Phytophthora capsici. Front Microbiol. 2016 Aug 4;7:1236. doi: 10.3389/fmicb.2016.01236. PMID: 27540377; PMCID: PMC4972815.
3. Bischoff A, Stickan-Verfürth M, Michel MC. Effects of Nifedipine on Renal and Cardiovascular Responses to Neuropeptide Y in Anesthetized Rats. Molecules. 2021 Jul 24;26(15):4460. doi: 10.3390/molecules26154460. PMID: 34361613; PMCID: PMC8347858.
4. Lin YC, Wang JC, Wu MS, Lin YF, Chen CR, Chen CY, Chen KC, Peng CC. Nifedipine Exacerbates Lipogenesis in the Kidney via KIM-1, CD36, and SREBP Upregulation: Implications from an Animal Model for Human Study. Int J Mol Sci. 2020 Jun 19;21(12):4359. doi: 10.3390/ijms21124359. PMID: 32575412; PMCID: PMC7352626.
In vitro protocol:
1. Yu SS, Jiang LR, Ling Y, Qian ZM, Zhou YF, Li J, Ke Y. Nifedipine Increases Iron Content in WKPT-0293 Cl.2 Cells via Up-Regulating Iron Influx Proteins. Front Pharmacol. 2017 Feb 13;8:60. doi: 10.3389/fphar.2017.00060. PMID: 28243203; PMCID: PMC5303744.
2. Liu P, Gong J, Ding X, Jiang Y, Chen G, Li B, Weng Q, Chen Q. The L-type Ca(2+) Channel Blocker Nifedipine Inhibits Mycelial Growth, Sporulation, and Virulence of Phytophthora capsici. Front Microbiol. 2016 Aug 4;7:1236. doi: 10.3389/fmicb.2016.01236. PMID: 27540377; PMCID: PMC4972815.
In vivo protocol:
1. Bischoff A, Stickan-Verfürth M, Michel MC. Effects of Nifedipine on Renal and Cardiovascular Responses to Neuropeptide Y in Anesthetized Rats. Molecules. 2021 Jul 24;26(15):4460. doi: 10.3390/molecules26154460. PMID: 34361613; PMCID: PMC8347858.
2. Lin YC, Wang JC, Wu MS, Lin YF, Chen CR, Chen CY, Chen KC, Peng CC. Nifedipine Exacerbates Lipogenesis in the Kidney via KIM-1, CD36, and SREBP Upregulation: Implications from an Animal Model for Human Study. Int J Mol Sci. 2020 Jun 19;21(12):4359. doi: 10.3390/ijms21124359. PMID: 32575412; PMCID: PMC7352626.
1: Shekhar S, Gupta N, Kirubakaran R, Pareek P. Oral nifedipine versus intravenous labetalol for severe hypertension during pregnancy: a systematic review and meta-analysis. BJOG. 2016 Jan;123(1):40-7. doi: 10.1111/1471-0528.13463. Epub 2015 Jun 26. Review. PubMed PMID: 26113232.
2: Toal CB, Meredith PA, Elliott HL. Long-acting dihydropyridine calcium-channel blockers and sympathetic nervous system activity in hypertension: a literature review comparing amlodipine and nifedipine GITS. Blood Press. 2012 Jul;21 Suppl 1:3-10. doi: 10.3109/08037051.2012.690615. Epub 2012 Jul 5. Review. PubMed PMID: 22762301; PubMed Central PMCID: PMC3469239.
3: Derosa G, Maffioli P. Nifedipine and telmisartan for the treatment of hypertension: the TALENT study. Expert Rev Cardiovasc Ther. 2011 Dec;9(12):1499-503. doi: 10.1586/erc.11.155. Review. PubMed PMID: 22103868.
4: Wilcox CB, Nassar N, Roberts CL. Effectiveness of nifedipine tocolysis to facilitate external cephalic version: a systematic review. BJOG. 2011 Mar;118(4):423-8. doi: 10.1111/j.1471-0528.2010.02824.x. Epub 2010 Dec 24. Review. PubMed PMID: 21199292.
5: Conde-Agudelo A, Romero R, Kusanovic JP. Nifedipine in the management of preterm labor: a systematic review and metaanalysis. Am J Obstet Gynecol. 2011 Feb;204(2):134.e1-20. doi: 10.1016/j.ajog.2010.11.038. Review. PubMed PMID: 21284967; PubMed Central PMCID: PMC3437772.
6: Furmaga EM, Glassman PA, Cunningham FE, Good CB. Reducing the Use of Short-acting Nifedipine by Hypertensives Using a Pharmaceutical Database. In: Henriksen K, Battles JB, Marks ES, Lewin DI, editors. Advances in Patient Safety: From Research to Implementation (Volume 3: Implementation Issues). Rockville (MD): Agency for Healthcare Research and Quality (US); 2005 Feb. PubMed PMID: 21249978.
7: Lundy A, Lutfi N, Beckey C. Review of nifedipine GITS in the treatment of high risk patients with coronary artery disease and hypertension. Vasc Health Risk Manag. 2009;5(1):429-40. Review. PubMed PMID: 19475779; PubMed Central PMCID: PMC2686260.
8: De Souza AR, Amorim MR, Costa AR. [Nifedipine antihypertensive treatment effects in pre-eclampsia]. Acta Med Port. 2008 Jul-Aug;21(4):351-8. Epub 2008 Oct 24. Review. Portuguese. PubMed PMID: 19094810.
9: Sierra C, Coca A. The ACTION study: nifedipine in patients with symptomatic stable angina and hypertension. Expert Rev Cardiovasc Ther. 2008 Sep;6(8):1055-62. doi: 10.1586/14779072.6.8.1055. Review. PubMed PMID: 18793108.
10: Kuwajima I. [Antihypertensive effects of nifedipine and changing for modified-release formula]. Drugs. 2006;66 Spec No 1:7-9. Review. Japanese. Erratum in: Drugs. 2007;67(13):1849. PubMed PMID: 18203344.
11: Komuro I. [Can nifedipine prevent aging of blood vessels?]. Drugs. 2006;66 Spec No 1:34-6. Review. Japanese. Erratum in: Drugs. 2007;67(13):1849. PubMed PMID: 18200779.
12: Horiuchi M. [Anti-inflammatory effect of nifedipine and vasculoprotection]. Drugs. 2006;66 Spec No 1:28-30. Review. Japanese. Erratum in: Drugs. 2007;67(13):1849. PubMed PMID: 18200777.
13: Yoshino G. [J-MIND study: effect of nifedipine on renal function in Japanese hypertensive patients with diabetes mellitus]. Drugs. 2006;66 Spec No 1:22-4. Review. Japanese. Erratum in: Drugs. 2007;67(13):1849. PubMed PMID: 18200775.
14: Hasebe N. [NICE-Combi study: effect of nifedipine in combination with an angiotensin II receptor blocker on BP control and renal protection]. Drugs. 2006;66 Spec No 1:16-8. Review. Japanese. Erratum in: Drugs. 2007;67(13):1849. PubMed PMID: 18200773.
15: Shimokawa H. [ACTION study: efficacy of nifedipine in preventing cardiovascular disease in patients with coronary artery disease]. Drugs. 2006;66 Spec No 1:10-2. Review. Japanese. Erratum in: Drugs. 2007; 67(13):1849. PubMed PMID: 18200771.
16: Kragten JA, Dunselman PH. Nifedipine Gastrointestinal Therapeutic System (GITS) in the treatment of coronary heart disease and hypertension. Expert Rev Cardiovasc Ther. 2007 Jul;5(4):643-53. Review. PubMed PMID: 17605643.
17: Lyndrup J, Lamont RF. The choice of a tocolytic for the treatment of preterm labor: a critical evaluation of nifedipine versus atosiban. Expert Opin Investig Drugs. 2007 Jun;16(6):843-53. Review. PubMed PMID: 17501696.
18: Lamont RF, Khan KS, Beattie B, Cabero Roura L, Di Renzo GC, Dudenhausen JW, Helmer H, Svare J, van Geijn HP; Steering Group of the International Preterm Labour Council. The quality of nifedipine studies used to assess tocolytic efficacy: a systematic review. J Perinat Med. 2005;33(4):287-95. Review. PubMed PMID: 16207113.
19: Yamagishi S, Takeuchi M. Atheroprotective properties of nifedipine. Int J Tissue React. 2005;27(2):63-7. Review. PubMed PMID: 16035650.
20: King JF, Flenady V, Papatsonis D, Dekker G, Carbonne B. Calcium channel blockers for inhibiting preterm labour; a systematic review of the evidence and a protocol for administration of nifedipine. Aust N Z J Obstet Gynaecol. 2003 Jun;43(3):192-8. Review. PubMed PMID: 14712983.
